Oncopeptides AB

Oncopeptides AB is a biopharmaceutical company specializing in the development and commercialization of therapies targeting difficult-to-treat hematological diseases. With a core focus on oncology, Oncopeptides leverages its proprietary peptide-drug conjugate technology, designed to improve the delivery of therapeutic agents directly to cancer cells, thereby enhancing efficacy while minimizing side effects. This technology enables the development of targeted treatments with the potential to transform the standard of care in multiple myeloma and other hematological malignancies. Oncopeptides AB plays a significant role within the pharmaceutical and healthcare sectors, particularly in the areas of research and development of oncological therapeutics. By focusing on niche, underserved patient populations, the company addresses significant medical needs and contributes to advancements in cancer treatment paradigms. Based in Sweden, Oncopeptides has a prominent presence in the European oncology market, further expanding its influence through strategic partnerships and clinical collaborations worldwide.